XBiotech Statistics
Total Valuation
XBiotech has a market cap or net worth of $68.60 million. The enterprise value is -$56.34 million.
Important Dates
The last earnings date was Friday, March 13, 2026, after market close.
| Earnings Date | Mar 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
XBiotech has 30.49 million shares outstanding. The number of shares has increased by 0.09% in one year.
| Current Share Class | 30.49M |
| Shares Outstanding | 30.49M |
| Shares Change (YoY) | +0.09% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 37.38% |
| Owned by Institutions (%) | 7.74% |
| Float | 19.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.49 |
| P/TBV Ratio | 0.49 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.01
| Current Ratio | 16.01 |
| Quick Ratio | 15.88 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -632.78 |
Financial Efficiency
Return on equity (ROE) is -28.23% and return on invested capital (ROIC) is -322.70%.
| Return on Equity (ROE) | -28.23% |
| Return on Assets (ROA) | -19.93% |
| Return on Invested Capital (ROIC) | -322.70% |
| Return on Capital Employed (ROCE) | -39.17% |
| Weighted Average Cost of Capital (WACC) | 9.14% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$535,765 |
| Employee Count | 85 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, XBiotech has paid $235,000 in taxes.
| Income Tax | 235,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.89 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 2.40 |
| 200-Day Moving Average | 2.63 |
| Relative Strength Index (RSI) | 41.65 |
| Average Volume (20 Days) | 49,558 |
Short Selling Information
The latest short interest is 118,904, so 0.39% of the outstanding shares have been sold short.
| Short Interest | 118,904 |
| Short Previous Month | 108,774 |
| Short % of Shares Out | 0.39% |
| Short % of Float | 0.62% |
| Short Ratio (days to cover) | 4.54 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -55.69M |
| Pretax Income | -45.31M |
| Net Income | -45.54M |
| EBITDA | -54.00M |
| EBIT | -55.69M |
| Earnings Per Share (EPS) | -$1.49 |
Full Income StatementBalance Sheet
The company has $125.55 million in cash and n/a in debt, with a net cash position of $125.55 million or $4.12 per share.
| Cash & Cash Equivalents | 125.55M |
| Total Debt | n/a |
| Net Cash | 125.55M |
| Net Cash Per Share | $4.12 |
| Equity (Book Value) | 140.35M |
| Book Value Per Share | 4.60 |
| Working Capital | 119.02M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$39.92 million and capital expenditures -$289,000, giving a free cash flow of -$40.21 million.
| Operating Cash Flow | -39.92M |
| Capital Expenditures | -289,000 |
| Depreciation & Amortization | 1.69M |
| Net Borrowing | -10.25M |
| Free Cash Flow | -40.21M |
| FCF Per Share | -$1.32 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
